“The SHE Biobank is a large, long-term study that will investigate the impact of genetic predisposition and environmental exposure to the development of disease,” said Madani. “Biobanking is crucial to this research and helps researchers, healthcare providers and governments to health policies and assign resources properly. “In recent years, due to advancements in healthcare technologies, data availability and decreasing DNA sequencing costs, various biobanks have been created around the world. However, the majority of such projects have been launched in developed countries, contributing to an increasing gap between developed and developing countries. This initiative aims to decrease that gap,” she said.
The SHE Biobank is unique in the educational support it offers researchers to conduct studies and the infrastructure it provides so the data can be put into action for public good. It also helps increase readiness of the healthcare community to prevent or combat future disease outbreaks.
“The recent COVID-19 pandemic has shown the importance of availability of digital health platforms to provide access to data and enable research and collaboration at scale for a large size of population,” said Shayan Mashatian, Founder of Silverberry Genomix. “By making the Silverberry platform available to this critical endeavor, we are facilitating a rapid launch of the project, connecting the researchers, healthcare institutions and other interested parties so more people can take advantage of scientific advancement, preventing disease or empower emerging field of precision medicine.”
Researchers, universities, government agencies, companies, and foundations as well as individual participants, are invited to participate in the initiative.
For more information about the initiative visit https://shebiobank.org or contact [email protected]
Original post https://alertarticles.info